Neuren Media and Analyst Coverage, page-1638

If you're referring to portraying the company in the best light possible to attract investor attention, maybe they do need help. But it wouldn't be the first time a company has remained nondescript and gone on to be a successful entity where revenues do the talking.

I understand your point, but I dont think it's an issue for Jon and Co. They are presenting facts and a little blue sky in the presentations when they talk about 5 X Retts opportunity, if they didn't do anymore then this wouldn't be far removed from several other Aussie biotechs imo. You do have companies like Clinuvel who constantly state timelines about developments and never adhere to them, the pattern of which its clearly obvious they are stringing people along until something does happen. This is a real pain in the a$$, analysts and by extension the market have publicly questioned Clinuvel's ability to deliver.

Neuren is the complete opposite, they give reasonable timelines that are 99% adhered to. They are consistent, the messaging is consistent if lacking a little finesse but they are reliable. They engender a lot more trust than the likes of Clinuvel. I like that, unsexy as it is.

I reiterate that Neuren is at a crossroads, and to your point about needing help I think Neuren is in the middle of preparing for that (with the recent hire of Daryl DeKarske which by the way suggests to me that they are going to run 2 Phase 3 trials concurrently with the second trial starting perhaps 9-12 months after the start of PMS trial. Makes sense to me that if they want to increase value substantially in a shorter period of time they would run 2 trials together). Jon doesn't want to sell the drug, he's possibly loathe to set up HQ in the US. But until such time they receive a suitable offer from a suitor or a very lucrative partnership, he has no choice but to keep advancing the company as if they will sell the drug themselves which will require more hands on deck.